Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma

Cancer Biomarkers

Volumn 11, Issue 1, 2011, Pages 49-58

  Mareĉko, Ilona ^a   Cvejić, Dubravka ^a   Tatić, Svetislav ^a   Dragutinović, Vesna ^a   Paunović, Ivan ^a,b   Savin, Svetlana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

clinico pathological parameters; Human fetal thyroid; immunohistochemistry; matrix metalloproteinase 2; papillary thyroid carcinoma; tissue inhibitors of matrix metalloproteinase 2

Indexed keywords

GELATINASE A; PARAFFIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER PROGNOSIS; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FETUS; FETUS (ANATOMY); FETUS DEVELOPMENT; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; TISSUE SECTION; TUMOR VOLUME;

ADENOMA; ADOLESCENT; ADULT; AGED; CARCINOMA; CHILD; DIAGNOSIS, DIFFERENTIAL; FETUS; HUMANS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PROGNOSIS; QUINOLINES; RETROSPECTIVE STUDIES; ROC CURVE; STATISTICS, NONPARAMETRIC; THYROID GLAND; THYROID NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84864479766     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-0258     Document Type: Article

References (35)

1. Z.W. Baloch and V.A. Livolsi, Follicular-patterned lesions of the thyroid: The bane of the pathologist. Am J Clin Pathol 117 (2002), 143-150.
2. R.V. Lloyd, L.A. Erickson, M.B. Casey, K.Y. Lam, C.M. Lohse, S.L. Asa, et al., Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28 (2004), 1336-1340.
3. H. Nagase and J.F. Woessner, Matrix metalloproteinases, J Biol Chem 30 (1999), 21491-21494.
4. I. Stamenkovic, Extracellular matrix remodelling: The role of matrix metalloproteinases, J Pathol 200 (2003), 448-464.
5. M.W. Yeh, J.P. Rougier, J.W. Park, Q.Y. Duh, M. Wong, Z. Werb, et al., Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A, Endocr Relat Cancer 13 (2006), 1173-1183.
6. E. Baldini, M. Toller, F.M. Graziano, F.P. Russo, M. Pepe, L. Biordi, et al., Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines, Thyroid 14 (2004), 881-888.
7. X. Tian, M. Cong, W. Zhou, J. Zhu, Q. Liu, Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer, J Int Med Res 36 (2008), 699-703.
8. D.E. Gomez, D.F. Alonso, H. Yoshiji, U.P. Thorgeirsson, Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions, Eur J Cell Biol 74 (1997), 111-122.
9. E. Morgunova, A. Tuuttila, U. Bergmann, K. Tryggvason, Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2, Proc Natl Acad Sci U S A 99 (2002), 7414-7419.
10. E. Campo, M.J. Merino, L. Liotta, R. Neumann, W. Stetler- Stevenson, Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue, Hum Pathol 23 (1992), 1395-1401.
11. K. ChoMar, T. Eimoto, H. Tateyama, Y. Arai, Y. Fujiyoshi, M. Hamaguchi, Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions, Histopathology 48 (2006), 286-294.
12. D. Cvejic, S. Savin, I. Paunovic, S. Tatic, M. Havelka, Immunohistochemical localisation of matrix metalloproteinase- 2 (MMP-2) in medullary thyroid carcinoma. Arch Oncol 8 (2001), 95-98.
13. S. Korem, Z. Kraiem, E. Shiloni, O. Yehezkel, O. Sadeh, M.B. Resnick, Increased expression of matrix metalloproteinase-2: A diagnostic marker but not prognostic marker of papillary thyroid carcinoma, Isr Med Assoc J 4 (2002), 247-251.
14. H. Nakamura, H. Ueno, K. Yamashita, T. Shimada, E. Yamamoto, M. Noguchi, et al., Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas, Cancer Res 59 (1999), 467-473.
15. M. Rydlova, L. Holubec Jr, M. Ludvikova Jr, D. Kalfert, J. Franekova, C. Povysil, et al., Biological activity and clinical implications of the matrix metalloproteinases, Anticancer Res 28 (2008), 1389-1397.
16. R. Canete-soler, Y.H. Gui, K.K. Linask, R.J. Muschel, Developmental expression of MMP-9 (gelatinase B) mRNA in mouse embryos, Developmental Dynamics 204 (1995), 30-40.
17. L. Sobin and C.H. Wittekind, in: TNM classification of malignant tumors, PA: Wiley-Liss, New York, 1997.
18. T.H. Shepard, Onset of function in the human fetal thyroid: Biochemical and radioautographic studies from organ culture, J Clin Endocrinol Metab 27 (1967), 945-958.
19. J.E. Pinter, Normal development of the hypothalamicpituitarythyroid axis. in: The Thyroid, Braverman LE, Utiger RD, eds, Werner and Ingbars. 7th ed., Philadelphia, New York, Lippincott-Raven, 1996, pp. 6-18.
20. J. Sinadinovic, S. Savin, J.V. Micic, Some characteristics of soluble thyroid proteins in human fetus during morphogenesis of follicular structure, Exp Clin Endocrinol 88 (1986), 346-354.
21. J. Bocian-Sobkowska, W. Wozniak, L.K. Malendowicz, Morphometric studies on the development of the human thyroid gland. II. The late fetal life, Histol Histopathol 12 (1997), 79-84.
22. A. Page-McCaw, A.J. Ewald, Z. Werb, Matrix metalloproteinases and the regulation of tissue remodeling, Nat Rev Mol Cell Biol 8 (2007), 221-233.
23. H. Maeta, S. Ohgi, T. Terada, Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas, Virchows Arch 438 (2001), 121-128.
24. A. Hofmann, S. Laue, A.K. Rost, W.A. Scherbaum, G. Aust, mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines, hyroid 8 (1998), 203-214.
25. J.Y. Choi, J.S. Bae, Y.A. Kim, E.D. Chang, H.J. Cho, K.H. Kim, et al., Clinical significance ofMMP-2,MMP-9 and HIF- 1 alpha expression in thyroid micropapillary cancer. Korean Surg Soc 78 2010), 157-164.
26. B.G. Cavalheiro, C.R. Junqueira, L.G. Brandao, Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: Prognostic implications, Thyroid 18 (2008), 865-871.
27. S. DAlessio, G. Ferrari, K. Cinnante, W. Scheerer, A.C. Galloway, D.F. Roses, et al., Tissue inhibitor of metalloproteinases- 2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. J Biol Chem 283 (2008), 87-99.
28. W.G. Stetler-Stevenson, Tissue inhibitors of metalloproteinases in cell signaling: Metalloproteinase-independent biological activities. Sci Signal 1 (2008) re6.
29. F. Roca, L.V. Mauro, A. Morandi, F. Bonadeo, C. Vaccaro, G.O. Quintana, et al., Prognostic value of E-cadherin, betacatenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg Oncol 93 (2006), 151-160.
30. H. Ruokolainen, P. Paakko, T. Turpeenniemi-Hujanen, Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma-tissue immunoreactivity predicts aggressive clinical course. Mod Pathol 19 (2006), 208-217.
31. T. Yoshizaki, Y. Maruyama, H. Sato, M. Furukawa, Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 95 (2001), 44-50.
32. B.G. Cavalheiro, C.R. Junqueira, L.G. Brandao, Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 135 (2009), 812-817.
33. Z. Wang, R. Juttermann, P.D. Soloway, TIMP-2 is required for efficient activation of proMMP-2 in vivo, J Biol Chem 275 (2000), 26411-26415.
34. A. Noel, C. Maillard, N. Rocks, M. Jost, V. Chabottaux, N.E. Sounni et al., Membrane associated proteases and their inhibitors in tumour angiogenesis, J Clin Pathol 57 (2004), 577-584.
35. T. Shiomi and Y. Okada, MT1-MMP and MMP-7 in invasion and metastasis of human cancers, Cancer Metastasis Rev 22 (2003), 145-152.